OCULAR THERAPEUTIX INC. - COMMON STOCK

Ocular Therapeutix™ to Present at Two Investor Conferences in September

04 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Reports Second Quarter 2024 Results

07 Aug 2024 07:10:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD

07 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

31 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

30 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

10 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

13 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

Ocular Therapeutix® to Host Investor Day on June 13, 2024

05 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Reports First Quarter 2024 Results

07 May 2024 16:05:00 By Nasdaq GlobeNewswire

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 May 2024 20:16:23 By Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

06 May 2024 07:30:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

03 May 2024 07:30:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

01 May 2024 07:30:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

18 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

16 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

15 Apr 2024 07:00:00 By Nasdaq GlobeNewswire